Abstract | BACKGROUND: METHODS: Twenty-three non-diabetic depressed males were recruited and assigned to two groups based on the antidepressants received ( maprotiline n=11, fluoxetine n=12). The severity of depression was evaluated using a 21-item Hamilton depression rating scale (HAM-D). Before and after the 4-week treatment, participants underwent 75-g oral glucose tolerance test (OGTT) and frequently sampled intravenous glucose tolerance test (FSIGT). Insulin sensitivity (SI), glucose effectiveness (SG), acute insulin response (AIR), and disposition index (DI) were estimated using minimal model method. RESULTS: The HAM-D scores were reduced significantly (P<0.005) after antidepressant treatment. Following maprotiline treatment, the body weight and BMI were significantly increased (P=0.02). Individuals treated with maprotiline displayed a significantly increased AIR (3239+/-682 vs. 4698+/-597 pmol; P=0.04) during the FSIGT. LIMITATIONS: The sample size was limited. Furthermore, the study was conducted in the early phase of depression-treated course. CONCLUSIONS:
|
Authors | Yi-Chyan Chen, Yu-Chih Shen, Yi-Jen Hung, Chao-Ha Chou, Chin-Bin Yeh, Cheng-Hwang Perng |
Journal | Journal of affective disorders
(J Affect Disord)
Vol. 103
Issue 1-3
Pg. 257-61
(Nov 2007)
ISSN: 0165-0327 [Print] Netherlands |
PMID | 17320192
(Publication Type: Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Adrenergic Uptake Inhibitors
- Antidepressive Agents, Second-Generation
- Blood Glucose
- Insulin
- Serotonin Uptake Inhibitors
- Fluoxetine
- Maprotiline
|
Topics |
- Adrenergic Uptake Inhibitors
(adverse effects, therapeutic use)
- Adult
- Antidepressive Agents, Second-Generation
(adverse effects, therapeutic use)
- Blood Glucose
(metabolism)
- Body Mass Index
- Body Weight
(drug effects)
- Depressive Disorder, Major
(blood, drug therapy)
- Fluoxetine
(adverse effects, therapeutic use)
- Glucose Tolerance Test
- Homeostasis
(drug effects)
- Humans
- Insulin
(blood)
- Insulin Resistance
- Insulin-Secreting Cells
(drug effects)
- Male
- Maprotiline
(adverse effects, therapeutic use)
- Personality Inventory
- Selective Serotonin Reuptake Inhibitors
(adverse effects, therapeutic use)
|